h38C2 IgG1-ADC

**h38C2 IgG1-ADC** is a site-specific antibody–drug conjugate (ADC) based on the humanized catalytic monoclonal antibody h38C2 in immunoglobulin G1 (IgG1) format. This antibody contains a uniquely reactive lysine residue (Lys99) in a deep hydrophobic pocket, allowing selective covalent attachment of cytotoxic payloads via β-lactam or 1,3-diketone functionalized linkers, forming a stable amide bond and ensuring homogeneity of the conjugate[1][2][5][7]. The h38C2 IgG1 can be further engineered into a dual-variable domain (DVD) format, incorporating an outer antigen-binding fragment for cancer cell targeting (e.g. HER2, CD138, CD79B, TrkB) and retaining the inner h38C2 fragment for site-specific drug conjugation[1][3][5][7]. The primary mechanism is highly efficient, stable, and precise conjugation without additional protein engineering, enabling rapid assembly and strict target-dependent cytotoxicity in vitro and potent activity in vivo[1][3][5]. The platform supports various targeting domains, allowing use against different cancers (e.g., breast cancer, multiple myeloma, lymphoma, triple-negative breast cancer)[1][3][5][6]. Payloads used include monomethyl auristatin F (MMAF) and other cytotoxics[2][5]. Development has progressed to preclinical and early clinical trials[1][2][3].

Other names

h38C2-ADCh-38C2-ADCh 38C2-ADCh38C2 DVD-ADCh-38C2 DVD-ADCh 38C2 DVD-ADC